Research on emerging COVID-19 (target, mechanism, and therapeutics)

September 28, 2020

Acta Pharmaceutica Sinica B publishes special issue on 'Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)' edited by Hai-Bin Luo, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; Shilin Chen, Institute of Chinese Materia Medica, Beijing, China and Peiqing Liu, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. In recent months, due to its high infectivity and pathogenicity, SARS-CoV-2 has gradually spread to more than 200 countries and regions, resulting in more than 500,000 deaths globally. There is an urgent need for effective prevention and treatment (drugs and vaccines) against this highly pathogenic coronavirus. This special issue includes original five research articles, three review articles, and two letters to the editor covering topics around the identification of readily available drugs or natural products as a rapid way to provide clinical treatment in COVID-19 therapy.

Featured papers in this issue are:

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 by authors Xiaoyan Liu, Zhe Li, Shuai Liu, Jing Sun and Hai-Bin Luo (https://doi.org/10.1016/j.apsb.2020.04.008). Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, the authors found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, the authors identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro.

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites by authors Sisi Kang, Mei Yang, Zhongsi Hong, Liping Zhang and Shoudeng Chen (https://doi.org/10.1016/j.apsb.2020.04.009). The structural information of SARS-CoV-2 nucleocapsid protein remains unclear. The authors have determined the 2.7 Å crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein and revealed potential unique drug targeting sites, which can help guide the design of novel antiviral agents targeting SARS-CoV-2.

D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 by authors Yulong Shi, Xinben Zhang, Kaijie Mu, Cheng Peng and Weiliang Zhu (https://doi.org/10.1016/j.apsb.2020.04.006). The authors have developed a molecular docking-based web server D3Targets-2019-nCoV to accelerate drug discovery against COVID-19. The server has two functions; one, to predict targets for active compounds, and two, to identify potent compounds via virtual screening. The webserver is useful to medical chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against SARS-CoV-2.

Other articles published in the issue include:

Review articles

Combating COVID-19 with integrated traditional Chinese and Western medicine in China Liqiang Ni, Lili Chen, Xia Huang, Chouping Han, Hongzhuan Chen https://doi.org/10.1016/j.apsb.2020.06.009

Bioactive natural compounds against human coronaviruses: a review and perspective Yanfang Xian, Juan Zhang, Zhaoxiang Bian, Hua Zhou, Hongxi Xu https://doi.org/10.1016/j.apsb.2020.06.002

Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight Chunting He, Ming Qin, Xun Sun https://doi.org/10.1016/j.apsb.2020.05.009

Original articles

Analysis on herbal medicines utilized for treatment of COVID-19
Lu Luo, Jingwen Jiang, Cheng Wang, Martin Fitzgerald, Shilin Chen
https://doi.org/10.1016/j.apsb.2020.05.007

Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model
Cheng Cui, Miao Zhang, Xueting Yao, Siqi Tu, Dongyang Liu
https://doi.org/10.1016/j.apsb.2020.04.007

Letters to the Editor
Comment on GLP-1-based drugs and COVID-19 treatment
Tianru Jin, Mingyao Liu
https://doi.org/10.1016/j.apsb.2020.05.006

Anti-RAS drugs and SARS-CoV-2 infection
Jingwei Bian, Rongsheng Zhao, Suodi Zhai, Zijian Li
https://doi.org/10.1016/j.apsb.2020.04.013

Keywords: SARS-CoV-2; COVID-19; Prevention; Treatment
-end-
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.

Acta Pharmaceutica Sinica B (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics. For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/

Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

CiteScore: 10.5
Impact Factor: 7.097
5-Year Impact Factor: 7.865
Source Normalized Impact per Paper (SNIP): 2.210
SCImago Journal Rank (SJR): 1.792ISSN 2211-3835

Compuscript Ltd

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.